MedTrace Logo

Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System

NCT02690805 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2021-04-19

No results posted yet for this study

Summary

The purpose of this research study is to investigate the accuracy of a breast imaging system that measures the uptake of the injected radioactive tracer by gamma-ray imaging, known as scinti-mammography (SMM), to diagnose the residual breast cancer after neoadjuvant chemotherapy (NAC) treatment by comparing to MRI.

Conditions

Interventions

DEVICE

MR-compatible scinti-mammography (MRI-SMM) system

Sponsors & Collaborators

  • University of California, Irvine

    lead OTHER

Eligibility

Min Age
21 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2019-01-25
Completion
2019-01-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02690805 on ClinicalTrials.gov